Five Primary Human Pancreatic Adenocarcinoma Cell Lines Established by the Outgrowth Method

Rückert, Felix; Aust, D.; Böhme, I; Werner, Kristin; Brandt, Aljoscha; Diamandis, Eleftherios P.; Krautz, Christian; Hering, Sandra; Saeger, Hans‐Detlev; Grützmann, Robert; Pilarsky, Christian

doi:10.1016/j.jss.2011.04.021

Cited by 59 publications

(69 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression of vimentin in cancer cells is one of the manifestations of epithelial-mesenchymal transition [13,18,24]. Expression of vimentin in PDAC cells is mentioned in about 45% of cases, that statistically significantly differs from our study, where the expression of vimentin was found in 20.4% (95% CI = 11.5-33.2) pancreatic carcinoma cases.…”

Section: Discussioncontrasting

confidence: 96%

“…5-65.9). This is in accordance with several other studies that have described the mean age of PDAC patients as 60.5 to 65 years [15,24,25]. Considering the CI, our study shows slight but statistically significant difference with the publication of Yang et al, where the mean age is 67 years [11].…”

Section: Discussionsupporting

confidence: 92%

“…In our group, the tumour size exceeded 3 cm in 68.2% (95% CI = 53.4-80.0) cases that also is statistically significantly more than in other studies, where it was 42% and 139/356 (39.1%), respectively [13,25]. There is a statistically significant difference in the N1 parameter between our data, namely, 67.2% (95% CI = 54.7-77.7) and other three studies -37.0%, 193/396 (48.7%) and 80.0% [12,24,25]. Although in our study we found no correlation between N stage and survival rate, in other studies presence of lymph node metastases is described as a significant factor (p = 0.01 or 0.05) that affects the survival [12,13].…”

Section: Discussioncontrasting

confidence: 58%

“…However, in our study there was no significant relation between these factors. Similarly to Bcl-2, vimentin expression is related to the resistance to chemotherapy [13,24,25].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Factors after Curative Resection of Pancreatic Ductal Adenocarcinoma: a Retrospective Study

Štrumfa¹,

Simtniece²,

Āboliņš³

et al. 2012

J Cancer Ther Res

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 96%

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 58%

“…However, in our study there was no significant relation between these factors. Similarly to Bcl-2, vimentin expression is related to the resistance to chemotherapy [13,24,25].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Factors after Curative Resection of Pancreatic Ductal Adenocarcinoma: a Retrospective Study

Štrumfa¹,

Simtniece²,

Āboliņš³

et al. 2012

J Cancer Ther Res

View full text Add to dashboard Cite

show abstract

“…The success rate of this method was reported to be approximately 10% in experienced hands, 12 although most groups do not publish failed attempts. 13e16 Conversely, in other cancer types, cell line derivation from patient-derived xenotransplantation demonstrates up to 10 times the success rate compared with that from cancer specimens at the time of resection.…”

mentioning

confidence: 99%

Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture

Pham

Delitto

Knowlton

et al. 2016

The American Journal of Pathology

View full text Add to dashboard Cite

Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells

et al. 2015

View full text Add to dashboard Cite

Oncolytic viruses have demonstrated in pre-clinical and clinical studies safety and a unique pleiotropic activity profile of tumor destruction. Yet, their delivery suffers from virus inactivation by blood components and sequestration to healthy tissues. Therefore, mesenchymal stromal cells (MSCs) have been applied as carrier cells for shielded virus delivery to tumors after ex vivo infection with oncolytic viruses. However, infection and particle production by MSCs have remained unsatisfying. Here, we report engineered oncolytic adenoviruses (OAds) for improved virus production and delivery by MSCs. OAds are uniquely amenable to molecular engineering, which has facilitated improved tumor cell destruction. But for MSC-mediated regimens, OAd engineering needs to achieve efficient infection and replication in both MSCs and tumor cells. We show that an Ad5/3 chimeric OAd capsid, containing the adenovirus serotype 3 cell-binding domain, strongly increases the entry into human bone marrow-derived MSCs and into established and primary pancreatic cancer cells. Further, we reveal that OAd with engineered post-entry functions-by deletion of the anti-apoptotic viral gene E1B19K or expression of the death ligand TRAIL-markedly increased virus titers released from MSCs, while MSC migration was not hampered. Finally, these virus modifications, or viral expression of FCU1 for local 5-FC prodrug activation, improved tumor cell killing implementing complementary cytotoxicity profiles in a panel of pancreatic cancer cell cultures. Together, our study establishes post-entry modification of OAd replication for improving virus delivery by carrier cells and suggests a panel of optimized OAds for future clinical development in personalized treatment of pancreatic cancer.

show abstract

Five Primary Human Pancreatic Adenocarcinoma Cell Lines Established by the Outgrowth Method

Cited by 59 publications

References 21 publications

Prognostic Factors after Curative Resection of Pancreatic Ductal Adenocarcinoma: a Retrospective Study

Prognostic Factors after Curative Resection of Pancreatic Ductal Adenocarcinoma: a Retrospective Study

Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture

Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells

Contact Info

Product

Resources

About